Key result
Intracardiac thrombus developed in 6% of children with dilated cardiomyopathy, all of whom had an LVEF >30% and were not receiving antiaggregant therapy, while mean LVEF did not differ between those with and without thrombus (35.2% vs 34.7%, p=0.910).
Why the study?
Does antiaggregant therapy prevent intracardiac thrombus in children with dilated cardiomyopathy?
Cohort (n=83)
No
Does antiaggregant therapy prevent intracardiac thrombus in children with dilated cardiomyopathy?
Absolute Event Rate: 35.2% vs 34.7%
p-value: p=0.910
Intracardiac thrombus can develop in children with dilated cardiomyopathy even with LVEF >30%, suggesting a potential role for prophylactic antithrombotic therapy at diagnosis regardless of LVEF.
No takes yet. Share an insight, caveat, or question.
Thrombus risk in pediatric DCM may occur with LVEF >30% without antiaggregants; hypothesis-generating for early prophylaxis, pending prospective trials.
Ahmet İrdem (2014) conducted a cohort in Dilated cardiomyopathy (n=83). Intracardiac thrombus vs. No intracardiac thrombus was evaluated on Mean Left Ventricular Ejection Fraction (LVEF) (p=0.910). Intracardiac thrombus developed in 6% of children with dilated cardiomyopathy, all of whom had an LVEF >30% and were not receiving antiaggregant therapy, while mean LVEF did not differ between those with and without thrombus (35.2% vs 34.7%, p=0.910).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: